Sebastian Wiberg1, Christian Hassager2, Henrik Schmidt2, Jakob Hartvig Thomsen2, Martin Frydland2, Matias Greve Lindholm2, Dan Eik Høfsten2, Thomas Engstrøm2, Lars Køber2, Jacob Eifer Møller2, Jesper Kjaergaard2. 1. From Department of Cardiology, The Heart Centre, Copenhagen University Hospital, Rigshospitalet, Denmark (S.W., C.H., J.H.T., M.F., M.G.L., D.E.H., T.E., L.K., J.K.); Department of Anaesthesiology and Intensive care, Odense University Hospital, Denmark (H.S.); and Department of Cardiology, Odense University Hospital, Denmark (J.E.M.). sebastian.christoph.wiberg@regionh.dk. 2. From Department of Cardiology, The Heart Centre, Copenhagen University Hospital, Rigshospitalet, Denmark (S.W., C.H., J.H.T., M.F., M.G.L., D.E.H., T.E., L.K., J.K.); Department of Anaesthesiology and Intensive care, Odense University Hospital, Denmark (H.S.); and Department of Cardiology, Odense University Hospital, Denmark (J.E.M.).
Abstract
BACKGROUND: In-hospital mortality in comatose patients resuscitated from out-of-hospital cardiac arrest (OHCA) is ≈50%. In OHCA patients, the leading cause of death is neurological injury secondary to ischemia and reperfusion. Glucagon-like peptide-1 analogs are approved for type 2 diabetes mellitus; preclinical and clinical data have suggested their organ-protective effects in patients with ischemia and reperfusion injury. The aim of this trial was to investigate the neuroprotective effects of the glucagon-like peptide-1 analog exenatide in resuscitated OHCA patients. METHODS: We randomly assigned 120 consecutive comatose patients resuscitated fromOHCA in a double-blind, 2-center trial. They were administered 17.4 μg exenatide (Byetta) or placebo over a 6-hour and 15-minute infusion, in addition to standardized intensive care including targeted temperature management. The coprimary end points were feasibility, defined as initiation of the study drug in >90% patients within 240 minutes of return of spontaneous circulation, and efficacy, defined as the geometric area under the neuron-specific enolase curve from 24 to 72 hours after admission. The main secondary end points included a composite end point of death and poor neurological function, defined as a Cerebral Performance Category score of 3 to 5 assessed at 30 and 180 days. RESULTS: The study drug was initiated within 240 minutes of return of spontaneous circulation in 96% patients. The median blood glucose 8 hours after admission in patients receiving exenatide was lower than that in patients receiving placebo (5.8 [5.2-6.7] mmol/L versus 7.3 [6.2-8.7] mmol/L, P<0.0001). However, there were no significant differences in the area under the neuron-specific enolase curve, or a composite end point of death and poor neurological function between groups. Adverse events were rare with no significant difference between groups. CONCLUSIONS: Acute administration of exenatide to comatose patients in the intensive care unit after OHCA is feasible and safe. Exenatide did not reduce neuron-specific enolase levels and did not significantly improve a composite end point of death and poor neurological function after 180 days. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT02442791.
RCT Entities:
BACKGROUND: In-hospital mortality in comatosepatients resuscitated from out-of-hospital cardiac arrest (OHCA) is ≈50%. In OHCA patients, the leading cause of death is neurological injury secondary to ischemia and reperfusion. Glucagon-like peptide-1 analogs are approved for type 2 diabetes mellitus; preclinical and clinical data have suggested their organ-protective effects in patients with ischemia and reperfusion injury. The aim of this trial was to investigate the neuroprotective effects of the glucagon-like peptide-1 analog exenatide in resuscitated OHCA patients. METHODS: We randomly assigned 120 consecutive comatosepatients resuscitated from OHCA in a double-blind, 2-center trial. They were administered 17.4 μg exenatide (Byetta) or placebo over a 6-hour and 15-minute infusion, in addition to standardized intensive care including targeted temperature management. The coprimary end points were feasibility, defined as initiation of the study drug in >90% patients within 240 minutes of return of spontaneous circulation, and efficacy, defined as the geometric area under the neuron-specific enolase curve from 24 to 72 hours after admission. The main secondary end points included a composite end point of death and poor neurological function, defined as a Cerebral Performance Category score of 3 to 5 assessed at 30 and 180 days. RESULTS: The study drug was initiated within 240 minutes of return of spontaneous circulation in 96% patients. The median blood glucose 8 hours after admission in patients receiving exenatide was lower than that in patients receiving placebo (5.8 [5.2-6.7] mmol/L versus 7.3 [6.2-8.7] mmol/L, P<0.0001). However, there were no significant differences in the area under the neuron-specific enolase curve, or a composite end point of death and poor neurological function between groups. Adverse events were rare with no significant difference between groups. CONCLUSIONS: Acute administration of exenatide to comatosepatients in the intensive care unit after OHCA is feasible and safe. Exenatide did not reduce neuron-specific enolase levels and did not significantly improve a composite end point of death and poor neurological function after 180 days. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT02442791.
Authors: Elliot J Glotfelty; Thomas Delgado; Luis B Tovar-Y-Romo; Yu Luo; Barry Hoffer; Lars Olson; Tobias Karlsson; Mark P Mattson; Brandon Harvey; David Tweedie; Yazhou Li; Nigel H Greig Journal: ACS Pharmacol Transl Sci Date: 2019-02-11
Authors: Jerry P Nolan; Claudio Sandroni; Bernd W Böttiger; Alain Cariou; Tobias Cronberg; Hans Friberg; Cornelia Genbrugge; Kirstie Haywood; Gisela Lilja; Véronique R M Moulaert; Nikolaos Nikolaou; Theresa Mariero Olasveengen; Markus B Skrifvars; Fabio Taccone; Jasmeet Soar Journal: Intensive Care Med Date: 2021-03-25 Impact factor: 17.440
Authors: Sebastian Wiberg; Jesper Kjaergaard; Rasmus Møgelvang; Christian Holdflod Møller; Kristian Kandler; Hanne Ravn; Christian Hassager; Lars Køber; Jens Christian Nilsson Journal: BMJ Open Date: 2021-11-05 Impact factor: 2.692
Authors: Martin A S Meyer; Sebastian Wiberg; Johannes Grand; Jesper Kjaergaard; Christian Hassager Journal: Trials Date: 2020-10-20 Impact factor: 2.279
Authors: Dario A Vitturi; Charles Maynard; Michele Olsufka; Adam C Straub; Nick Krehel; Peter J Kudenchuk; Graham Nichol; Michael Sayre; Francis Kim; Cameron Dezfulian Journal: Redox Biol Date: 2020-02-14 Impact factor: 10.787